Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APRE NASDAQ:CMND NASDAQ:CVKD NASDAQ:EGRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$0.74$0.83$0.55▼$2.22$9.18M1.5108,634 shs131,524 shsCMNDClearmind Medicine$2.36$3.89$2.04▼$524.00$2.40M0.742.63 million shs65,940 shsCVKDCadrenal Therapeutics$3.60$4.52$2.55▼$14.64$10.33M1.7390,792 shs107,092 shsEGRXEagle Pharmaceuticals$0.67$0.53$0.00▼$3.87$8.70M0.839,769 shsN/AAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics0.00%-6.20%-5.36%+3.58%-56.41%CMNDClearmind Medicine0.00%-0.84%-20.00%-78.15%-99.35%CVKDCadrenal Therapeutics0.00%+18.03%-16.47%-23.40%-71.06%EGRXEagle Pharmaceuticals0.00%0.00%+27.62%+167.89%-76.86%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$0.74$0.83$0.55▼$2.22$9.18M1.5108,634 shs131,524 shsCMNDClearmind Medicine$2.36$3.89$2.04▼$524.00$2.40M0.742.63 million shs65,940 shsCVKDCadrenal Therapeutics$3.60$4.52$2.55▼$14.64$10.33M1.7390,792 shs107,092 shsEGRXEagle Pharmaceuticals$0.67$0.53$0.00▼$3.87$8.70M0.839,769 shsN/AAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics0.00%-6.20%-5.36%+3.58%-56.41%CMNDClearmind Medicine0.00%-0.84%-20.00%-78.15%-99.35%CVKDCadrenal Therapeutics0.00%+18.03%-16.47%-23.40%-71.06%EGRXEagle Pharmaceuticals0.00%0.00%+27.62%+167.89%-76.86%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 2.40Hold$4.07448.81% UpsideCMNDClearmind Medicine 0.00N/AN/AN/ACVKDCadrenal Therapeutics 2.00Hold$13.00261.11% UpsideEGRXEagle Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CMND, APRE, CVKD, and EGRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026APREAprea Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$7.00 ➝ $6.005/7/2026APREAprea Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$5.004/20/2026APREAprea Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026CVKDCadrenal Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/7/2026CVKDCadrenal Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$32.00 ➝ $13.00(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$290K31.63N/AN/A$1.52 per share0.49CMNDClearmind MedicineN/AN/AN/AN/A$11.28 per shareN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/A$1.17 per shareN/AEGRXEagle Pharmaceuticals$257.55M0.03$1.68 per share0.40N/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$12.60M-$1.54N/AN/AN/A-4,405.59%-61.03%-50.24%8/11/2026 (Estimated)CMNDClearmind Medicine-$3.86M-$139.98N/AN/AN/AN/A-143.79%-88.51%N/ACVKDCadrenal Therapeutics-$13.24M-$5.63N/AN/AN/AN/A-411.03%-275.61%8/10/2026 (Estimated)EGRXEagle Pharmaceuticals$35.64M$1.180.57N/AN/AN/AN/AN/A8/11/2026 (Estimated)Latest CMND, APRE, CVKD, and EGRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/15/2026Q2 2026CMNDClearmind MedicineN/A-$6.78N/A-$6.78N/AN/A5/13/2026Q1 2026APREAprea Therapeutics-$0.23-$0.22+$0.01-$0.22$0.00 millionN/A5/7/2026Q4 2025CVKDCadrenal Therapeutics-$1.51-$1.04+$0.47-$1.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/ACMNDClearmind MedicineN/AN/AN/AN/AN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A8.928.92CMNDClearmind MedicineN/A4.794.79CVKDCadrenal TherapeuticsN/A2.682.68EGRXEagle PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%CMNDClearmind Medicine96.05%CVKDCadrenal Therapeutics7.92%EGRXEagle Pharmaceuticals85.36%Insider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics10.49%CMNDClearmind MedicineN/ACVKDCadrenal Therapeutics26.09%EGRXEagle Pharmaceuticals28.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics712.38 million11.08 millionNo DataCMNDClearmind MedicineN/A1.02 millionN/ANot OptionableCVKDCadrenal Therapeutics42.87 million2.12 millionNot OptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataCMND, APRE, CVKD, and EGRX HeadlinesRecent News About These CompaniesEagle Pharmaceuticals (NASDAQ:EGRX) Stock Crosses Above 50-Day Moving Average - Time to Sell?June 24, 2026 | americanbankingnews.comDid Eagle Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?April 9, 2026 | prnewswire.comEagle Pharmaceuticals Announces Divestiture of BarhemsysJanuary 14, 2026 | globenewswire.comHALPER SADEH LLC ENCOURAGES EAGLE PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTSDecember 24, 2025 | prnewswire.comHalper Sadeh LLC Encourages Eagle Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their RightsDecember 7, 2025 | businesswire.comEagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights PlanOctober 30, 2025 | finanznachrichten.deEagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights PlanOctober 30, 2025 | finance.yahoo.comEagle Pharmaceuticals Announces Results of 2025 Annual Meeting of StockholdersOctober 21, 2025 | markets.businessinsider.comEagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial StatementsOctober 15, 2025 | globenewswire.comEagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial StatementsOctober 6, 2025 | globenewswire.comEagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal YearsSeptember 17, 2025 | globenewswire.comEagle Pharmaceuticals to Appoint Abhinav Jain to its Board of DirectorsAugust 28, 2025 | globenewswire.comEagle Pharmaceuticals Announces 2025 Annual Meeting DateAugust 18, 2025 | globenewswire.comEagle Pharmaceuticals, Inc. (EGRX) - Yahoo FinanceJuly 10, 2025 | finance.yahoo.comEGRX Eagle Pharmaceuticals, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comEagle Pharmaceuticals Insider Trading Activity | OTC:EGRX | BenzingaApril 28, 2025 | benzinga.comEagle Pharmaceuticals announces $69M pact to monetize Bendeka royaltiesApril 1, 2025 | markets.businessinsider.comEagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® RoyaltiesMarch 31, 2025 | markets.businessinsider.comEagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights PlanMarch 21, 2025 | globenewswire.comEagle Pharma Founder Sues Company to Recoup Cost of SEC InvestigationNovember 23, 2024 | law.comLNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMND, APRE, CVKD, and EGRX Company DescriptionsAprea Therapeutics NASDAQ:APRE$0.74 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$0.78 +0.04 (+5.26%) As of 07/2/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Clearmind Medicine NASDAQ:CMND$2.36 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$2.33 -0.03 (-1.40%) As of 07/2/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.Cadrenal Therapeutics NASDAQ:CVKD$3.60 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$3.56 -0.04 (-0.97%) As of 07/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Eagle Pharmaceuticals NASDAQ:EGRX$0.67 0.00 (0.00%) As of 07/2/2026Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
